Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5219642
Max Phase: Preclinical
Molecular Formula: C48H68N12O19
Molecular Weight: 1117.14
Associated Items:
ID: ALA5219642
Max Phase: Preclinical
Molecular Formula: C48H68N12O19
Molecular Weight: 1117.14
Associated Items:
Canonical SMILES: CC(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@H]1CCCCC[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C(=O)O)C(=O)O)C(N)=O)NC(=O)[C@H](Cc2ccc([N+](=O)[O-])cc2)NC(=O)[C@H](CCC(N)=O)NC1=O)C(C)C
Standard InChI: InChI=1S/C48H68N12O19/c1-22(2)37(52-24(4)61)46(73)59-18-8-11-34(59)45(72)55-29-10-7-5-6-9-28(41(68)58-33(21-36(63)64)43(70)51-23(3)39(66)56-31(38(50)65)20-27(47(74)75)48(76)77)53-44(71)32(19-25-12-14-26(15-13-25)60(78)79)57-42(69)30(54-40(29)67)16-17-35(49)62/h12-15,22-23,27-34,37H,5-11,16-21H2,1-4H3,(H2,49,62)(H2,50,65)(H,51,70)(H,52,61)(H,53,71)(H,54,67)(H,55,72)(H,56,66)(H,57,69)(H,58,68)(H,63,64)(H,74,75)(H,76,77)/t23-,28-,29-,30-,31-,32-,33-,34-,37-/m0/s1
Standard InChI Key: UWUBSFPMKFWHGU-SMLZLRLCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1117.14 | Molecular Weight (Monoisotopic): 1116.4724 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Krzyzanowski A, Esser LM, Willaume A, Prudent R, Peter C, 't Hart P, Waldmann H.. (2022) Development of Macrocyclic PRMT5-Adaptor Protein Interaction Inhibitors., 65 (22.0): [PMID:36378254] [10.1021/acs.jmedchem.2c01273] |
Source(1):